Meeting
2013 ASCO Annual Meeting
Safety and efficacy of ipilimumab in melanoma patients who received prior immunotherapy on phase III study MDX010-020.
Authors
Howard Kaufman
Rush University Medical Center, Chicago, IL
Howard Kaufman , Jose Lutzky , Joseph Clark , Kim Allyson Margolin , David H. Lawson , Asim Amin , Frances A. Collichio , Andrew Pecora , Walter John Urba , Kelly L. Bennett , David F. McDermott
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT00094653
Citation
J Clin Oncol 31, 2013 (suppl; abstr 9050)
DOI
10.1200/jco.2013.31.15_suppl.9050
Abstract #
9050
Poster Bd #
45E
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).
First Author: Dirk Schadendorf
Poster
2023 ASCO Annual Meeting
A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.
First Author: Daniel Olson
Poster
2015 ASCO Annual Meeting
Phase III trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL).
First Author: Owen A. O'Connor
Poster
2014 ASCO Annual Meeting
Phase 3 trial of brentuximab vedotin and CHP versus CHOP in the frontline treatment of patients (pts) with CD30+ mature T-cell lymphomas (MTCL).
First Author: Owen A. O'Connor